Antasthmatic Market BreakDown Briefing
作者:wangchun 来源Q本站原?nbsp; 点击敎ͼ0 更新旉Q?007-1-16 12:31:05
[关键字]Q?/font> Antasthmatic
健康|讯Q?/FONT>
Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published:
Format: Hardcopy and Adobe PDF
Price: US$2,100
Contact: Mr. Bian chenghua Ms. Wu huifang
Tel.: 86-10-68012929-2105/2101 Fax: 86-10-68052505
E-mail: bianch@healthoo.com wuhf@healthoo.com
Table of contents
Summary
1. Epidemiology of asthma and market scales
1.1 Morbidity rate
1.2 Market scales
2. Categories, mechanism of action and application of antasthmatic
2.1 Categories of antasthmatic
2.2 Mechanism of action and application of antasthmatic
3. Market scales and growth trend of antasthmatic
3.1 Drugs shares in hospital and growth rate from 2002 to 2005
3.2 Drugs shares of competitive enterprises in hospital from 2002 to
2005
3.3 Rank of antasthmatic from 2002 to 2005
4. Typical antasthmatic market breakdown
4.1 β receptor agonists
Salbutamol
Terbutaline
Procaterol
Salmeterol
Formoterol
Bambuterol
4.2 Phosphodiesterase inhibitors
Theopylline
Doxofylline
Hyphylline
Aminophylline
4.3 Anticholinergic agents
Ipratropium Bromide
4.4 Leukotriene receptor antagonist
Montelukast
Zafirlukast
4.5 Glucocorticosteroid
Budesonide
Beclometasone
Fluticasone propionate
4.6 Compound preparation
Asmeton “strong?capsules
Salmeterol Xinafoate and Fluticasone Propionate
5. Market scales and growth rate of key breeds
5.1 Market scales and growth rate of Budesonide
5.2 Market scales and growth rate of Salmeterol Xinafoate and Flutica
sone Propionate
5.3 Market scales and growth rate of Formoterol
5.4 Market scales and growth rate of Montelukast
6. The appraisal of antasthmatic API demands in China
7. Development of new products
7.1 Application institution of new drugs
7.2 Introduction of developing new drugs which is not yet or about to
China
Appendix 1 Breeds of Basic Medical Insurance Medicine List in 2004
Appendix 2 Products of antasthmatic drugs approved by SFDA
Tables and figures
Table 1 Categories of antasthmatic drugs
Table 2 Growth rate of sales values of Antasthmatic drugs from 2002 to
2005
Table 3 Antasthmatic drugs shares of enterprises from 2002 to 2005
Table 4 Top 20 best-selling Antiasthmatic drugs in 2005
Table 5 Top 20 best-selling Antiasthmatic drugs in 2004
Table 6 Top 20 best-selling Antiasthmatic drugs in 2003
Table 7 Top 20 best-selling Antiasthmatic drugs in 2002
Table 8 Top 10 Antiasthmatic drugs ranked by average annual growth from
2002 to 2005
Table 9 Top 20 leading enterprises for Salbutamol in 2005
Table 10 Top 20 leading enterprises for Terbutaline in 2005
Table 11 Top 20 leading enterprises for Procaterol in 2005
Table 12 Top 20 leading enterprises for Salmeterol in 2005
Table 13 Top 20 leading enterprises for Formoterol in 2005
Table 14 Top 20 leading enterprises for Bambuterol in 2005
Table 15 Top 20 leading enterprises for Theophylline in 2005
Table 16 Top 20 leading enterprises for Doxofylline in 2005
Table 17 Top 20 leading enterprises for Diprophylline in 2005
Table 18 Top 20 leading enterprises for Aminophylline in 2005
Table 19 Top 20 leading enterprises for Ipratropium Bromide in 2005
Table 20 Top 20 leading enterprises for Montelukast in 2005
Table 21 Top 20 leading enterprises for Zafirlukast in 2005
Table 22 Top 20 leading enterprises for Budesonide in 2005
Table 23 Top 20 leading enterprises for Beclometasone in 2005
Table 24 Top 20 leading enterprises for Fluticasone Propionate in 2005
Table 25 Top 20 leading enterprises for Asmeton “strong?Capsules in
2005
Table 26 Top 20 leading enterprises for Salmeterol Xinafoate and
Fluticasone Propionate in 2005
Table 27 Sales values and growth rate of Budesonide of different
enterprises from 2002 to 2005
Table 28 Sales values and growth rate of Salmeterol Xinafoate and
Fluticasone Propionate of different enterprises from 2002 to 2005
Table 29 Sales values and growth rate of Formoterol of different
enterprises from 2002 to 2005
Table 30 Sales values and growth rate of Montelukast of different
enterprises from 2002 to 2005
Table 31 New drugs of Budesonide approved by SFDA from 2003 to 2006
Table 32 New drugs of Formoterol approved by SFDA from 2003 to 2006
Table 33 Antiasthmatic drugs of Basic Medical Insurance Medicine List
in 2004
Figure 1 Sales values of Antiasthmatic drugs from 2002 to 2005
Figure 2 Market shares of major enterprises of Antiasthmatic drugs in
2005
Figure 3 Sales values and growth rate of Budesonide from 2002 to 2005
Figure 4 Sales values of Budesonide of enterprises from 2002 to 2005
Figure 5 Sales values and growth rate of Salmeterol Xinafoate and
Fluticasone Propionate from 2002 to 2005
Figure 6 Sales values and growth rate of Formoterol from 2002 to 2005
Figure 7 Sales values of Formoterol of enterprises from 2002 to 2005
Figure 8 Sales values and growth rate of Montelukast from 2002 to 2005
Figure 9 Sales values of Montelukast of enterprises from 2002 to 2005